{
  "pathway_name": "bone-sarcoma-clinical-pathways-v1-2024-508h",
  "original_file": "bone-sarcoma-clinical-pathways-v1-2024-508h_extracted.json",
  "processed_at": "2025-03-29T01:40:00.283744",
  "complete_summary": {
    "response": "# COMPREHENSIVE CLINICAL PATHWAY FOR BONE SARCOMA MANAGEMENT\n\n## 1. INTRODUCTION\n\nThis clinical pathway provides evidence-based algorithms for the diagnosis, treatment, and surveillance of bone sarcomas, covering three primary types:\n- Chondrosarcoma\n- Ewing Sarcoma\n- Osteosarcoma\n\nTreatment approaches are stratified by disease type, stage, and specific clinical scenarios. Multidisciplinary consultation and expert pathology review are emphasized throughout all pathways.\n\n## 2. DIAGNOSTIC APPROACH AND INITIAL EVALUATION\n\n### Common Initial Diagnostic Workup\n- Adequate imaging of primary tumor (X-rays and contrast-enhanced MRI)\n- CT chest with contrast\n- Core needle biopsy with carefully planned needle track\n- Biopsy along future resection access with minimal dissection\n- Attention to hemostasis\n- Cytogenetics and/or molecular studies\n- Fertility consultation recommended prior to chemotherapy\n- Expert pathology review and sarcoma team consultation\n\n## 3. CHONDROSARCOMA PATHWAYS\n\n### 3.1 Standard Chondrosarcoma (Newly Diagnosed)\n\n#### Pathology-Based Classification\n- **Standard Chondrosarcoma**: Continue with protocol below\n- **De-differentiated Chondrosarcoma**: Follow Osteosarcoma pathway\n- **Mesenchymal Chondrosarcoma**: Follow Ewing Sarcoma pathway\n\n#### Treatment by Resectability\n- **Resectable disease** (including low-grade extra-compartmental appendicular tumors, grade I axial tumors, grade II-III tumors, clear cell or extra-compartmental tumors):\n  * Refer to Orthopedic Oncology\n  * Surveillance protocol\n- **Unresectable Tumors**:\n  * Refer to Radiation Oncology\n\n#### Surveillance\n- CT scan with contrast or MRI of affected area with and without contrast\n- CT chest every 6 months for 5 years, then annually for 10 years\n\n### 3.2 Chondrosarcoma, Recurrent or Metastatic\n\n#### Treatment by Disease Extent\n1. **Localized Disease**: Follow initial treatment pathway\n2. **Oligometastatic Disease**:\n   - If resectable: Surgery\n   - If unresectable: Radiation Oncology\n3. **Widespread Disease**:\n   - If symptomatic: Local therapy (surgery, radiation, ablation)\n   - If asymptomatic: Medical Oncology with options:\n     * If MSI-high/TMB \u226510: pembrolizumab\n     * If IDH1 mutations: ivosidenib\n     * Others: TKI therapy with dasatinib\n\n## 4. EWING SARCOMA PATHWAYS\n\n### 4.1 Initial Diagnosis and Treatment\n\n#### Treatment Algorithm\n1. **Induction Therapy**:\n   - Multi-agent chemotherapy (VDC/IE) for 9 weeks\n   - Restaging imaging\n   - Multidisciplinary discussion\n\n2. **Local Control**:\n   - If resectable with acceptable function:\n     * Surgical resection\n     * If positive margins: Radiation Oncology\n     * If negative margins: Continue chemotherapy\n   - If unresectable: Definitive radiation therapy\n\n3. **Adjuvant Therapy**:\n   - Continue VDC/IE for total course of 49 weeks as tolerated\n\n### 4.2 Induction Chemotherapy for Ewing Sarcoma\n\n#### Alternating Regimen Schedule (11-week protocol)\n- **Regimen A** (Weeks 1, 5, 9):\n  * Vincristine: 2 mg/m\u00b2 (max 2 mg), IV, Day 1\n  * Doxorubicin: 37.5 mg/m\u00b2, IV, Days 1-2 (omit during RT)\n  * Cyclophosphamide: 1200 mg/m\u00b2, IV with mesna, Day 1\n  * Filgrastim: 5 mcg/kg/day (max 300 mcg), starting Day 3\n\n- **Regimen B** (Weeks 3, 7, 11):\n  * Ifosfamide: 1800 mg/m\u00b2, IV with mesna, Days 1-5\n  * Etoposide: 100 mg/m\u00b2, IV, Days 1-5\n  * Filgrastim: 5 mcg/kg/day (max 300 mcg), starting Day 6\n\n### 4.3 Ewing Sarcoma (Progressive, Relapsed, or Metastatic)\n\n#### Disease Management\n1. **Progressive Disease/Local Relapse**:\n   - If amenable to local therapy: Follow established pathway\n   - If not: Cyclophosphamide and topotecan\n\n2. **Metastatic Disease**:\n   - If resectable and surgery-eligible: Surgery\n   - If resectable but surgery-ineligible: Radiation Oncology\n   - If unresectable: Chemotherapy\n\n3. **Chemotherapy Sequence**:\n   - First-line: VDC/IE (if not previously given) or continue assessment\n   - If progression:\n     * Second-line: Cyclophosphamide and topotecan\n     * Third-line: Regorafenib\n     * Fourth-line: Gemcitabine and Docetaxel\n\n4. **Imaging**: CT chest, abdomen, pelvis, primary site every 3 months\n\n## 5. OSTEOSARCOMA PATHWAYS\n\n### 5.1 Initial Diagnosis and Treatment\n\n#### Treatment by Subtype\n1. **Low-grade/parosteal osteosarcoma**:\n   - Wide excision\n   - If high-grade components: Chemotherapy\n   - If low-grade: Surveillance\n\n2. **Periosteal osteosarcoma**:\n   - If upfront resection: Wide excision \u2192 Grade assessment\n   - If no upfront resection: Chemotherapy\n\n3. **High-grade osteosarcoma**:\n   - Neoadjuvant chemotherapy (cisplatin/doxorubicin or methotrexate/leucovorin)\n   - Restaging\n   - If resectable: Wide resection \u2192 Response assessment:\n     * Positive margin, >90% necrosis: Complete chemotherapy + Surgery/RT\n     * Positive margin, <90% necrosis: Multidisciplinary re-planning\n     * Negative margin, >90% necrosis: Complete chemotherapy + Surveillance\n     * Negative margin, <90% necrosis: Multidisciplinary re-planning\n   - If unresectable: Radiation Oncology\n\n### 5.2 Osteosarcoma, Relapsed or Metastatic\n\n#### Management Pathways\n1. **Relapsed Local Disease**:\n   - If resectable: Orthopedic Oncology\n   - If unresectable: Consider RT for palliation \u2192 Assess response\n     * Complete response: Surveillance\n     * Incomplete response: Medical Oncology\n\n2. **Oligometastatic Disease**:\n   - Multidisciplinary discussion\n   - If candidate for local control: Refer appropriately\n   - If not: Medical Oncology\n\n3. **Widespread Disease**: Medical Oncology\n\n4. **Systemic Therapy Sequence**:\n   - First-line: Doxorubicin + cisplatin \u00b1 methotrexate\n   - Second-line: Etoposide + ifosfamide\n   - Subsequent: Regorafenib\n\n## 6. MOLECULAR TESTING PATHWAYS\n\n### Testing by Sarcoma Type\n1. **Chondrosarcoma (widespread/asymptomatic)**:\n   - DNA/RNA-based comprehensive genomic profiling\n\n2. **Suspected Ewing Sarcoma**:\n   - FISH or RT-PCR for EWSR1:FLI1 fusion (choose one)\n\n3. **Small round blue cell tumor (EWSR1:FLI1 negative)**:\n   - DNA/RNA-based comprehensive genomic profiling\n\n4. **Metastatic Osteosarcoma**:\n   - DNA/RNA-based comprehensive genomic profiling\n   - **Critical**: Biopsy from non-bony site, NO decalcification\n\n5. **Bone sarcoma, NOS**:\n   - DNA/RNA-based comprehensive genomic profiling\n\n## 7. SURVEILLANCE PROTOCOLS\n\n- **Chondrosarcoma**: CT/MRI of affected area + CT chest every 6 months (5 years), then annually (10 years)\n- **Ewing Sarcoma**: Physical exam/CBC + MRI/CT of primary site + CT chest every 3 months\n- **Osteosarcoma**: X-rays + contrast-enhanced MRI of affected area + CT chest\n\n## 8. SPECIAL CONSIDERATIONS\n\n- **Clinical Trials**: Consider at all treatment points (CancerClinicalTrialsNavigation@va.gov)\n- **Radiation Safety**: Omit doxorubicin during radiation therapy\n- **Chemotherapy Adjustments**: Based on patient tolerance\n- **Pathology Reclassification**:\n  * De-differentiated chondrosarcoma \u2192 Follow Osteosarcoma pathway\n  * Mesenchymal chondrosarcoma \u2192 Follow Ewing Sarcoma pathway\n- **Response Assessment**: Good response = \u226590% tumor necrosis; Poor response = <90%\n- **Multidisciplinary Approach**: Essential across all bone sarcoma management\n\nThis clinical pathway emphasizes personalized, evidence-based approaches to bone sarcoma management with appropriate molecular testing, multimodal treatment strategies, and long-term surveillance protocols based on specific disease characteristics.",
    "thinking": "Based on the detailed analyses of the provided pages, I'll now create a comprehensive summary of the bone sarcoma clinical pathway document. I'll organize it in a logical sequence that would be useful for clinicians, focusing on each type of bone sarcoma, including diagnostic approaches, treatment algorithms, surveillance protocols, and special considerations.\n\nLet me structure the summary as follows:\n1. Introduction and Overview\n2. Diagnostic Approach and Initial Evaluation\n3. Chondrosarcoma Pathways\n   - Standard Chondrosarcoma\n   - Recurrent or Metastatic Chondrosarcoma\n4. Ewing Sarcoma Pathways\n   - Initial Diagnosis and Treatment\n   - Induction Chemotherapy Protocol\n   - Progressive, Relapsed, or Metastatic Disease\n5. Osteosarcoma Pathways\n   - Initial Diagnosis and Treatment\n   - Relapsed or Metastatic Disease\n6. Molecular Testing Pathways\n7. Surveillance Protocols\n8. Special Considerations and Clinical Trial Information\n\nNow I'll draft the comprehensive summary:\n\n# COMPREHENSIVE CLINICAL PATHWAY FOR BONE SARCOMA MANAGEMENT\n\n## 1. INTRODUCTION AND OVERVIEW\n\nThis clinical pathway document provides evidence-based algorithms for the diagnosis, treatment, and surveillance of bone sarcomas. It covers three primary types of bone sarcomas:\n- Chondrosarcoma\n- Ewing Sarcoma\n- Osteosarcoma\n\nTreatment approaches are stratified by disease type, stage (newly diagnosed vs. relapsed/metastatic), and specific clinical scenarios. Multidisciplinary consultation and expert pathology review are emphasized throughout all pathways.\n\n## 2. DIAGNOSTIC APPROACH AND INITIAL EVALUATION\n\n### Initial Diagnostic Workup (Common Elements)\n- Adequate imaging of primary tumor (X-rays and contrast-enhanced MRI)\n- CT chest with contrast\n- Core needle biopsy with carefully planned needle track\n- Consider biopsy along future resection access with minimal dissection\n- Attention to hemostasis\n- Cytogenetics and/or molecular studies as indicated\n- Fertility consultation recommended prior to chemotherapy\n- Expert pathology review and sarcoma team consultation\n\n## 3. CHONDROSARCOMA PATHWAYS\n\n### 3.1 Standard Chondrosarcoma (Newly Diagnosed)\n\n#### Initial Assessment\n- Expert pathology review and sarcoma team consultation\n- Pathology-based classification:\n  * Standard Chondrosarcoma: continue with protocol below\n  * De-differentiated Chondrosarcoma: follow Osteosarcoma pathway\n  * Mesenchymal Chondrosarcoma: follow Ewing Sarcoma pathway\n\n#### Treatment by Resectability Assessment\n- **Resectable disease** (including low-grade extra-compartmental appendicular tumors, grade I axial tumors, grade II-III tumors, or clear cell or extra-compartmental tumors):\n  * Refer to Orthopedic Oncology for surgical management with appropriate margins\n  * Proceed to surveillance protocol\n\n- **Borderline or Unresectable Tumors**:\n  * Refer to Radiation Oncology\n\n#### Surveillance Protocol\n- CT scan with contrast or MRI of affected area with and without contrast\n- CT chest at least every 6 months for 5 years\n- Then annually for 10 years\n\n### 3.2 Chondrosarcoma, Recurrent or Metastatic\n\n#### Initial Assessment\n- Multidisciplinary team discussion\n- Expert pathology review and sarcoma team consultation\n\n#### Treatment by Disease Extent\n1. **Localized Disease**:\n   - Follow initial treatment pathway (standard protocol)\n\n2. **Oligometastatic Disease**:\n   - If resectable: Refer to Surgery\n   - If unresectable: Refer to Radiation Oncology\n\n3. **Widespread Disease**:\n   - If symptomatic: Refer for local therapy (surgery, radiation, or ablative therapies)\n   - If asymptomatic: Refer to Medical Oncology with the following treatment options:\n     * If microsatellite instability is high OR tumor mutation burden is \u226510 mutations per megabase: pembrolizumab\n     * If IDH1 mutations: ivosidenib\n     * For all others: consider TKI therapy with dasatinib\n\n## 4. EWING SARCOMA PATHWAYS\n\n### 4.1 Initial Diagnosis and Treatment\n\n#### Initial Workup\n- X-rays and contrast-enhanced MRI\n- CT chest with contrast\n- Core needle biopsy with carefully planned needle track\n- Cytogenetics and/or molecular studies\n- Fertility consultation recommended\n- Expert pathology review and sarcoma team consultation\n\n#### Treatment Algorithm\n1. **Induction Therapy**:\n   - Multi-agent chemotherapy (VDC/IE) for 9 weeks\n   - Restaging imaging\n   - Multidisciplinary discussion\n\n2. **Local Control (Decision Point)**:\n   - If resectable with acceptable functional outcome:\n     * Surgical resection\n     * Margin status assessment:\n       - If positive: Refer to Radiation Oncology\n       - If negative: Continue multi-agent chemotherapy\n   - If unresectable:\n     * Definitive radiation therapy\n     * Consider pre-operative and/or intraoperative radiation if surgical resection is planned later\n\n3. **Adjuvant Therapy**:\n   - Continue multi-agent chemotherapy (VDC/IE) for total course of 49 weeks as tolerated\n\n#### Surveillance Protocol\n- Physical exam including CBC\n- MRI or CT of primary site\n- CT chest\n- Frequency: Every 3 months\n\n### 4.2 Induction Chemotherapy Protocol for Ewing Sarcoma\n\n#### Regimen A (Weeks 1, 5, and 9)\n1. **Vincristine**: \n   - 2 mg/m\u00b2 (maximum 2 mg)\n   - IV over 1 minute\n   - Day 1\n\n2. **Doxorubicin**:\n   - 37.5 mg/m\u00b2\n   - IV over 1-15 minutes\n   - Days 1 and 2\n   - Omitted during radiation therapy\n\n3. **Cyclophosphamide**:\n   - 1200 mg/m\u00b2\n   - IV over 30-60 minutes\n   - Day 1\n   - With mesna\n\n4. **Filgrastim**:\n   - 5 mcg/kg per day (maximum 300 mcg)\n   - Starting day 3\n\n#### Regimen B (Weeks 3, 7, and 11)\n1. **Ifosfamide**:\n   - 1800 mg/m\u00b2\n   - IV over 1 hour\n   - Days 1-5\n   - With mesna\n\n2. **Etoposide**:\n   - 100 mg/m\u00b2\n   - IV over 1-2 hours\n   - Days 1-5\n\n3. **Filgrastim**:\n   - 5 mcg/kg per day (maximum 300 mcg)\n   - Starting day 6\n\n### 4.3 Ewing Sarcoma (Progressive, Relapsed, or Metastatic)\n\n#### Initial Assessment\n- Expert pathology review and sarcoma team consultation\n- Disease classification:\n  * Progressive disease following neoadjuvant chemotherapy or local relapse\n  * Metastatic disease\n\n#### Progressive Disease/Local Relapse Management\n- If amenable to local therapy: Follow established Ewing Sarcoma pathway for local therapies\n- If not amenable to local therapy: Administer cyclophosphamide and topotecan regimen\n\n#### Metastatic Disease Management\n1. **Initial Approach**:\n   - Multidisciplinary discussion required\n   - Assessment of candidacy for therapy\n\n2. **If Candidate for Therapy**:\n   - If disease is resectable and patient eligible for surgery: Refer to Surgery\n   - If disease is resectable but patient ineligible for surgery: Refer to Radiation Oncology\n   - If disease is unresectable: Proceed to Chemotherapy\n\n3. **Chemotherapy Decision Path**:\n   - If no prior VDC/IE: Administer VDC/IE regimen\n   - If prior VDC/IE: Continue assessment with VDC/IE\n   - After VDC/IE therapy, assess for progression:\n     * If no progression: Continue current therapy\n     * If progression: Proceed to second-line therapy\n\n4. **Treatment Lines for Progressive Disease**:\n   - First Line: Cyclophosphamide and topotecan\n   - Second Line: Regorafenib\n   - Subsequent Treatment: Gemcitabine and Docetaxel\n\n5. **Imaging Protocol**:\n   - CT of chest, abdomen, pelvis, and primary site every 3 months to assess disease response\n\n## 5. OSTEOSARCOMA PATHWAYS\n\n### 5.1 Initial Diagnosis and Treatment\n\n#### Initial Workup\n- X-rays and contrast-enhanced MRI\n- CT chest with contrast\n- Core needle biopsy with carefully planned needle track\n- Cytogenetics and/or molecular studies\n- Fertility consultation recommended\n- Expert pathology review and sarcoma team consultation\n- Multidisciplinary discussion\n\n#### Treatment by Disease Classification\n\n1. **Low-grade osteosarcoma/parosteal osteosarcoma**:\n   - Wide excision surgery\n   - Tumor grade assessment:\n     * If high-grade: Cisplatin and doxorubicin chemotherapy\n     * If low-grade: Surveillance\n\n2. **Periosteal osteosarcoma**:\n   - Decision point: Upfront resection?\n     * If YES: Wide excision \u2192 Tumor grade assessment:\n       - If high-grade: Cisplatin and doxorubicin chemotherapy\n       - If low-grade: Surveillance\n     * If NO: Cisplatin and doxorubicin chemotherapy\n\n3. **High-grade osteosarcoma**:\n   - Neoadjuvant chemotherapy (cisplatin and doxorubicin, or high dose methotrexate with leucovorin rescue based on patient fitness and tolerability)\n   - Restaging (MRI with contrast, x-rays of primary site, CT chest with contrast)\n   - Decision point: Resection?\n     * If YES: Wide resection \u2192 Margin status and response assessment:\n       - **Positive margin, >90% tumor necrosis**:\n         * Complete perioperative chemotherapy\n         * Multidisciplinary discussion\n         * Either Surgery OR Radiation\n         * Surveillance\n       - **Positive margin, <90% tumor necrosis**:\n         * Re-planned patient for multidisciplinary discussion\n       - **Negative margin, >90% tumor necrosis**:\n         * Complete perioperative chemotherapy\n         * Surveillance\n       - **Negative margin, <90% tumor necrosis**:\n         * Re-planned patient for multidisciplinary discussion\n     * If NO: Refer to Radiation Oncology\n\n4. **Extraskeletal Manifestation**:\n   - Follow non-abdominal Retroperitoneal Soft Tissue Sarcoma pathway\n\n#### Response Criteria\n- Good Response: \u226590% tumor necrosis\n- Poor Response: <90% tumor necrosis\n\n#### Surveillance Protocol\n- X-rays and contrast-enhanced MRI of the affected area\n- CT chest with contrast\n\n### 5.2 Osteosarcoma, Relapsed or Metastatic\n\n#### Initial Evaluation\n- Expert pathology review and sarcoma team consultation\n- Multidisciplinary discussion\n- Disease progression assessment\n\n#### Management Pathways\n\n1. **Relapsed Local Disease**:\n   - If resectable: Refer to Orthopedic Oncology \u2192 Surveillance\n   - If unresectable: Evaluate need for local therapy for symptom palliation\n     * If needed: Refer to Radiation Oncology \u2192 Assess response\n       - If complete response: Surveillance\n       - If incomplete response: Refer to Medical Oncology\n     * If not needed: Proceed to response assessment\n\n2. **Oligometastatic Disease**:\n   - Multidisciplinary discussion to determine approach\n   - If candidate for local control: Refer to appropriate specialty\n   - If not a candidate for local control: Refer to Medical Oncology\n\n3. **Metastatic Widespread Disease**:\n   - Direct referral to Medical Oncology\n\n#### Medical Oncology Treatment Protocol\n- First Line therapy: doxorubicin and cisplatin +/- methotrexate with leucovorin rescue (based on patient fitness and tolerability)\n- Second Line therapy: etoposide and ifosfamide (upon progression)\n- Subsequent therapy: regorafenib\n- Recommendation: obtain biopsy of metastatic lesion for tumor mutation burden\n\n#### Reassessment Protocol\n- Contrast-enhanced MRI of the affected area\n- CT chest with contrast\n- CT abdomen and pelvis\n\n## 6. MOLECULAR TESTING PATHWAYS\n\n### Testing by Sarcoma Type\n\n1. **Chondrosarcoma (widespread and asymptomatic)**:\n   - Test: DNA and RNA based comprehensive genomic profiling (CGP)\n   - Method: Somatic NGS\n   - Specimen: Tumor Tissue\n   - Vendors: Tempus or Foundation Heme\n   - Coverage: NPOP covered\n\n2. **Suspected Ewing Sarcoma (diagnostic workup)**:\n   - Option 1: FISH for EWSR1:FLI1 fusion\n     * Vendor: Local VA or locally contracted vendor\n     * Coverage: Not NPOP covered\n   - Option 2: RT-PCR for EWSR1:FLI1 fusion\n     * Vendor: Local VA or locally contracted vendor\n     * Coverage: Not NPOP covered\n   - Specimen: Tumor Tissue\n\n3. **Small round blue cell tumor (negative for EWSR1:FLI1 fusion)**:\n   - Test: DNA and RNA based comprehensive genomic profiling (CGP)\n   - Method: Somatic NGS\n   - Specimen: Tumor Tissue\n   - Vendors: Tempus or Foundation Heme\n   - Coverage: NPOP covered\n\n4. **Osteosarcoma (metastatic)**:\n   - Test: DNA and RNA based comprehensive genomic profiling (CGP)\n   - Method: Somatic NGS\n   - Specimen: Tumor Tissue\n   - Vendors: Tempus or Foundation Heme\n   - Coverage: NPOP covered\n   - Special consideration: Biopsy must be collected from non-bony site (soft tissue, lymph node, or other organ) and specimen should NOT be decalcified\n\n5. **Bone sarcoma, not otherwise specified**:\n   - Test: DNA and RNA based comprehensive genomic profiling (CGP)\n   - Method: Somatic NGS\n   - Specimen: Tumor Tissue\n   - Vendors: Tempus or Foundation Heme\n   - Coverage: NPOP covered\n\n### Critical Testing Notes\n- For small round blue cell tumors morphologically compatible with Ewing Sarcoma, perform either FISH or molecular testing (not both).\n- For bone sarcomas not otherwise specified (non-chondrosarcoma, non-osteosarcoma, and non-small round blue cell tumors), consultation is required with:\n  * Soft tissue pathology specialist for diagnosis\n  * Sarcoma specialist for therapeutic management\n- All testing requires tumor tissue\n- For metastatic osteosarcoma, biopsies from non-bony sites must NOT be decalcified to preserve molecular integrity\n\n## 7. GENERAL SURVEILLANCE PROTOCOLS\n\n### Chondrosarcoma Surveillance\n- CT scan with contrast or MRI of affected area with and without contrast\n- CT chest at least every 6 months for 5 years\n- Then annually for 10 years\n\n### Ewing Sarcoma Surveillance\n- Physical exam including CBC\n- MRI or CT of primary site\n- CT chest\n- Frequency: Every 3 months\n\n### Osteosarcoma Surveillance\n- X-rays and contrast-enhanced MRI of the affected area\n- CT chest with contrast\n\n## 8. SPECIAL CONSIDERATIONS\n\n### Clinical Trials\n- Clinical trial participation should be considered at all points in all pathways\n- For assistance finding a clinical trial: Contact CancerClinicalTrialsNavigation@va.gov\n\n### Treatment Modifications\n- Doxorubicin must be omitted during radiation therapy periods due to excessive toxicity\n- Chemotherapy regimens may need to be adjusted based on patient tolerance\n- For osteosarcoma, neoadjuvant chemotherapy options include:\n  * Cisplatin and doxorubicin\n  * High-dose methotrexate with leucovorin rescue (based on patient fitness and tolerability)\n\n### Pathology-Specific Considerations\n- Patients with de-differentiated chondrosarcoma pathology should follow the Osteosarcoma pathway\n- Patients with mesenchymal chondrosarcoma pathology should follow the Ewing Sarcoma pathway\n- Low-grade Osteosarcoma classification includes parosteal osteosarcoma"
  }
}